

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Qbrexza (glycopyrronium) cloth

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Qbrexza (glycopyrronium) cloth	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Qbrexza (glycopyrronium) cloth may be approved if the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to one topical aluminum chloride antiperspirant; **AND**
- II. Individual is 9 years of age or older; **AND**
- III. Individual has a diagnosis of primary axillary hyperhidrosis.

Requests for Qbrexza (glycopyrronium) cloth may **not** be approved if the following criteria are met:

- I. Individual has one of the following diagnoses:
 - A. Glaucoma; **OR**
 - B. Paralytic ileus; **OR**
 - C. Unstable cardiovascular status in acute hemorrhage; **OR**
 - D. Severe ulcerative colitis; **OR**
 - E. Toxic megacolon complicating ulcerative colitis; **OR**
 - F. Myasthenia gravis; **OR**
 - G. Sjogren's syndrome; **OR**
- II. Individual is currently using other anticholinergic medications (such as, but not limited to, benztropine, dicyclomine, oral glycopyrrolate, hyoscyamine, tolterodine, trospium, trihexyphenidyl).

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 14, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Primary Focal Axillary. International Hyperhidrosis Society. Available from: <https://www.sweathelp.org/treatments-hcp/clinical-guidelines/primary-focal-hyperhidrosis/primary-focal-axillary.html>. Accessed August 30, 2018.
6. Hyperhidrosis: Diagnosis and treatment. American Academy of Dermatology. Available from: <https://www.aad.org/public/diseases/dry-sweaty-skin/hyperhidrosis#treatment>. Accessed August 30, 2018.
7. Glaser DA, Hebert AA, Nast A, et.al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. *J Am Acad Dermatol*. 2018. doi: 10.1016/j.jaad.2018.07.002.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0346-19